Hoth Therapeutics
Hoth Therapeutics
HOTH
NASDAQ
1.12
USD
-0.88%
About
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ).
It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI.
Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 114.6K |
| Three Month Average Volume | 16.8M |
| High Low | |
| Fifty-Two Week High | 3.37 USD |
| Fifty-Two Week Low | 0.58 USD |
| Fifty-Two Week High Date | 13 Sep 2023 |
| Fifty-Two Week Low Date | 08 Aug 2024 |
| Price and Volume | |
| Current Price | 0.6939 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -6.65% |
| Thirteen Week Relative Price Change | -44.59% |
| Twenty-Six Week Relative Price Change | -52.90% |
| Fifty-Two Week Relative Price Change | -74.48% |
| Year-to-Date Relative Price Change | -59.31% |
| Price Change | |
| One Day Price Change | -0.87% |
| Thirteen Week Price Change | -40.69% |
| Twenty-Six Week Price Change | -48.22% |
| Five Day Price Change | -8.58% |
| Fifty-Two Week Price Change | -68.02% |
| Year-to-Date Price Change | -51.81% |
| Month-to-Date Price Change | 0.97% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.02738 USD |
| Book Value Per Share (Most Recent Quarter) | 1.74304 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 2.02738 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 1.74304 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.56744 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.30125 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.69097 USD |
| Normalized (Last Fiscal Year) | -2.30125 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.30125 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.69097 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.30125 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.69097 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 2.13709 USD |
| Cash Per Share (Most Recent Quarter) | 1.80168 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.30125 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -99999.99 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.67893 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 21.56% |
| Tangible Book Value (5 Year) | 124.39% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 58.15% |
| EPS Change (Trailing Twelve Months) | 72.64% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -9,654,840 |
| Net Debt (Last Fiscal Year) | -9,292,350 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 14 |
| Current Ratio (Most Recent Quarter) | 15 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -8,447,090 |
| Free Cash Flow (Trailing Twelve Months) | -8,023,650 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -50 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -96.38% |
| Return on Assets (Trailing Twelve Months) | -67.99% |
| Return on Assets (5 Year) | -157.07% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -112.58% |
| Return on Equity (Trailing Twelve Months) | -77.36% |
| Return on Equity (5 Year) | -182.56% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -110.40% |
| Return on Investment (Trailing Twelve Months) | -76.33% |
| Return on Investment (5 Year) | -177.32% |